MISPLACED MANDATE: AN EXAMINATION OF FDA'S SILICONE BREAST IMPLANT POLICY

DSpace/Manakin Repository

dc.contributor.advisor	Hutt, Peter Barton	en_US
dc.contributor.author	Granoff, Susan N.	en_US
dc.date.accessioned	2012-07-06T21:39:10Z
dc.date.issued	1995	en_US
dc.identifier.citation	MISPLACED MANDATE: AN EXAMINATION OF FDA'S SILICONE BREAST IMPLANT POLICY (1995 Third Year Paper)	en
dc.identifier.uri	http://nrs.harvard.edu/urn-3:HUL.InstRepos:8965595
dc.description.abstract	Why did the Food and Drug Administration (FDA) suddenly call for a forty-five day moratorium on silicone gel breast implants in 1 992 and then ban virtually all cosmetic breast implants' only months after an FDA advisory panel had recommended that silicone breast implants remain on the market for both reconstructive and cosmetic uses?2 Is FDA's policy, which remains in force today, justified? What is FDA's mandate, and has FDA overstepped it in banning cosmetic breast implants?	en
dc.language.iso	en_US	en
dash.license	LAA	en_US
dc.subject	Food and Drug Law	en
dc.subject	silicone breast implants	en
dc.subject	breast augmentation	en
dc.subject	cosmetic surgery	en
dc.title	MISPLACED MANDATE: AN EXAMINATION OF FDA'S SILICONE BREAST IMPLANT POLICY	en
dc.type	Paper (for course/seminar/workshop)	en_US
dc.date.available	2012-07-06T21:39:10Z